阿斯利康胃癌药物在晚期试验中使生存率翻倍 (AZN:NYSE)

2026-10-25 · seekingalpha.com

阿斯利康的胃癌药物在晚期试验中使生存率翻倍，提升了肿瘤学销售预期。

AstraZeneca (AZN) said its experimental stomach cancer treatment doubled survival time in a late-stage clinical trial, strengthening prospects for a medicine th...